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Abstract 
Biologists have uncovered some of the most basic mechanisms by which normal cells develop into cancerous tumors. 
These biological theories can be transformed into adequate mathematical models. For this reason, we attempt to study the 
evolution of cancer cells using the GWBP. The purpose of this paper is to study how the genetic algorithm (GA) can be 
used to follow the evolution of cancer and find optimal chemotherapeutic treatments.The development of GWBP give us 
the evolution of number of cancer cells for any patient if the death rate will defined experimentally, according to this value 
we can simulate the suitable chemotherapy treatments which cause the death of cancer, then determine the minimum 
dosage treatment injected using the GA optimization method. Analysis of these results gives us the objective function, 
who gives us a minimum in terms of number of cancer cells, with maximum in terms of cumulative treatment dosage. 
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1. Introduction  
Cancer is one of the major diseases that limited the human life; it is treated with surgery, radiation, 
chemotherapy, hormones, and immunotherapy. The development in cancer prevention, detection, treatment, 
and management is recently very advanced. Recently, many mathematical models of cancer mechanisms have 
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been developed to aid in the understanding of the biological processes of cancer. The interest in developing 
such models is their ability to regroup a large amount of information accumulated by biologists and, therefore, 
to find ways to follow the evolution of this disease and optimize suitable treatments. 
The concept of applying optimal control to different disease states starts by the mid of 70s and since then, 
it is the subject of various publications. In [1] engineering optimal control theory is applied to investigate on 
the drug regimen for reducing an experimental tumor cell population. Swan [1] presents a study that has used 
engineering optimal control theory for a chemotherapy problem. It involves a human tumor and minimizes the 
total amount of used drug for a specified value of tumor cell population. The first published review of optimal 
control problems in the general area of cancer research appeared in [2]. In later papers, for example [3] and 
[4], Swan provides evidence for the use of continuous delivery of drugs. An excellent general reference for 
this whole topic is [5]. But in [6], Zietz and Nicolini attempted a compromise between toxicity and cell kill by 
using an objective function that is a combination of tumor cell final and normal population. As a different 
methodology, like in [7] and [8], the application of drugs is matched up with the progression of the cells 
through the cell cycle. In [6] the optimal period for drug application corresponds approximately to the normal 
cell cycle time. Most of these references concern treatment of solid tumors or cancer treatment in general.  
Before reaching the optimization step we need to study the modelling of cancer cells. For this reason, we 
are interested to study models that describe the evolution of cancer cells, assembly the protocols of cancer 
treatment; to achieve the optimal problem allows us to give each patient the optimal treatment, while killing 
the largest number of cancer cells. 
 In fact, observations in biological cases are often presented in a fuzzy way. For this reason, we attempt to 
introduce probabilities, which are used in stochastic models. Among the various stochastic models that are 
able to describe biological processes, such as cancer, we have the following: Moran Model [20], Wright-
Fisher (WF) Model [9, 10, 11], Galton Watson branching process (GWBP) [12, 13], Markov chain Processes 
[14], and Model of Moolgavkar, Venzon, and Knudson (MVK) [15].  
However, in our studies real case of cancer were modelled according to the GWBP methodologies, 
simulated and optimized according to GA strategy. The GWBP model is a stochastic model that defines the 
pattern of population growth using sums of identical and independent (iid) random variables; the population 
evolves from generation to generation, with the individuals receiving iid numbers of children [12]. This model 
introduces the case of cancer in [13], but it was not applied to a real case and don't study the influence of 
treatment in the number of cancer cells. 
In this paper, we apply chemotherapy protocols on the GWBP model that deal with cancer cells evolution 
and determine their simulations and optimization according to different objective functions. The section II of 
this paper presents the description and the characteristics of the GWBP models used in this study and the new 
points added so that we can use this model in the optimization of real case of cancer. 
  Section III presents the case study of the real case for the colon cancer using GWBP model and its 
optimization. Finally, section IV presents the discussion, of the simulated model according to the new point 
added, and of the optimized model according to different objective functions. 
2. The Galton-Watson Branching Process  
2.1. Description 
The Galton Watson process is the oldest, simplest and best-known branching process, which can be 
described as follows [16].  
A single ancestor particle lives for exactly one unit of time, and at the moment of death, it produces a 
random number of progeny according to a prescribed probability distribution. Each of the first-generation 
progeny behaves as the initial particle did, independently of one another. Each particle lives for a unit of time 
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and produces a random number of progeny. Each of the second-generation progeny behaves in an identical 
way, and so forth. We will consider X to be a random variable with values in N that describe the number of 
children of one individual, i.e., the probability for i children is given by ( )P X i . Let ip be defined by 
( ) .iP X i p  Now, nZ is the population size in generation n, i.e., an N-valued random variable. 
Furthermore, let 1... Z nX X be i.i.d. random variables, distributed similar to X (the number of offspring of 
one individual). Then, 
1
Zn
n iZ X
                                                                                                                                          (1) 
will be the population in generation n+1, which consists of the offspring of a generation. This process is called 
a branching process and, more specifically, a Galton-Watson process (a general branching process may also 
live in continuous time) [21]. We assume that driver mutations reduce the probability that the cell will take 
 
Therefore, a cell with k driver mutations has a death probability and division probability as, respectively 
[6]: 
(1 ) 1k andd s b d                                                                                                    (2) 
The parameter s characterizes the selective advantage provided by a driver mutation, in (2) the influence of 
the treatment does not appear, based on this equation, we account for the effect of the drug on the growth of 
cells. Because the cells are characterized by their selective coefficient, then s will increase with the drug 
probability and vice versa (0 1)s . Thus, we will have: 
0 0.5 0.5 0.5 1 0.5s if q or s if q  
and q is the probability of providing u0 dose in chemotherapy treatment [14]. 
1 uq e                                                                                                                                          (3) 
According to (2) and (3), the influence of treatment in the GWBP is appearing as follow: 
(1 ) 1k andd q s b d                                                                                        (4) 
An important parameter in determining how the sequence {Zn}  behaves for large n is the offspring 
mean [5]: 
1
jp j
j
m
                                                                                                                                        
(5) 
Where Pj is the probability of the death or birth of a cell and j varies from 1 to the number of cancer cells 
available in the generation. This mean has been discussed in detail in [17]. 
2.2. Characteristics 
 This model works far away from the target theory and studies the transformation that occurs when the first 
cell (among many at risk within a definite cancer type) accumulates a set of driver mutations [18]. The driver 
mutations are the mutations that cause cancer cells to grow. The analysis of this model yields a simple 
algebraic equation, which requires the initial number of cancer cells, the death and birth rates of cells, the 
number of driver mutations, and the selective advantage [18]. According to [17], we studied the equations for 
the calculation of cancer cells. However, these equations do not take into consideration the treatment effect on 
the cells. In this paper, we have collected these equations and related the dose effect to the selective advantage. 
Additionally, we calculated the death and birth rates according to (2), and we have applied them to a real 
cancer type, colon cancer. We studied the cell simulations according to real chemotherapy treatment protocols. 
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3. Case Study  
Colon cancer will be used as the real case for the Branching Galton-Watson model because the parameters 
that represent this cancer are compatible with the parameters that describe the model. This case is 
characterized by the following parameters [19]: 
 Cancer cells divide once every four days. 
 Colon cancer requires 5 driver mutations to appear in the human body (k = 5). 
 Initial number of cancer cells, C0 = 6*108 or 12*10 cells. 
 Total amount of drug is u = 3200 mg/m2 [18]. 
The protocol treatment will be as follows: 
Simplified LV5FU2: Folinic acid 400 mg/m2 for 2 h placed in 250 ml G 5 %; then, 5 FU 400 mg/m2 for 10 
min placed in 100 ml de G 5 %; and then, 5 FU 2400 mg/m2 in continuous perfusion for 46 h placed in G 5 %. 
This protocol is repeated every 14 days for a period of 2 months [18]. 
3.1. Simulations 
Using MATLAB code, we determine the simulation curve of treatment protocol (Fig. 1), whose describe 
the number of cancer cells (c) in three cases (patient died (Fig. 4), patient cured (Fig. 3), and patient in stable 
case (Fig. 2) who need to repeat the protocol treatment after some time). In this model, the parameter that 
affects the result of the simulation is the death rate (d). 
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Fig. 1 Treatment protocol of colon cancer 
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Fig. 2 Evolution of cancer in stable case Fig.3 Evolution of cancer in cured case 
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Fig. 4 Evolution of cancer in died case 
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Fig. 5 Evolution of cancer cells after optimization Fig. 6 Cumulative treatment dosages after optimization 
3.2. Optimizations  
Now, using the GA, we show the result of the optimized protocol cited above, represented in Fig. 6, using 
five objectives functions according to (6) to show the best minimizing of cancer cells represented in Fig.5, for 
a patient in stable case.  
2 2 2 2, ( ) , ( log( ) ) , ( log log )
2 2
and ( ) ,2 2
max max
c :maximum number of cancer cellsmax
u :maximum dosage treatmentmax
T T T Tf f f f
c dt c u dt c c u dt c c u u dt
T T T Ti i i i
T f c u dt
c uTi
                                                     (6) 
4. Discussion 
Fig. 1 show the protocol treatment applied for the colon cancer, in this protocol we inject the drug with 
maximum dosage every 5 generations (20 days), the evolution of cancer cells varies according to the patient 
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case. In Fig. 2, we show the number of cancer cells for a patient in stable case, in this case d = 0.3 without 
treatment and d = 0.7 with treatment, starting with C0 = 8*107 cells, this number increase slowly throughout 
the treatment period, but in Fig.3 this number decrease during the treatment period because the patient have a 
higher death rate (d = 0.9) with treatment and d = 0.4 without treatment, finally, in Fig.4 the patient die after 
the number of cancer cells reach 1012 cells, this patient have a lower death rate (d = 0.1) without treatment and 
d = 0.5 with treatment, for this reason the cancer growing rapidly. In general, the death rate is less than 0.5 
without treatment, between 0.5 and 1 with treatment. In our cases the value of d is chosen by hazard to cover 
all the possibility.  
Without optimization the patients in three cases, cure, death or stable, receive a total amount of dosage of 
12800 mg/m2 during the treatment period. Appling the GA in our simulated model for a patient in stable case, 
using five objectives functions, give us the cumulative treatment through the period treatment in Fig. 5 and 
the number of cancer cells according this treatment dosage in Fig. 6. Analysis of this results show that the 
objective function 2
Tf
Ti
J C dt , give us a minimum in terms of number of cancer cells, with maximum in 
terms of cumulative treatment dosage (7920 mg/m2) compared with other  objectives functions, but this value 
is minimum according to the cumulative dosage without optimization. 
The GWBP give us the evolution of number of cancer cells for any patient if the death rate will defined 
experimentally, according to this value we can determine the minimum dosage treatment injected using the 
GA optimization method. 
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